Abstract

**Background:** Recent guidelines in the management of papillary thyroid microcarcinoma (PTMC) recommend limiting surgery. However, trends in the characteristics and management of PTMC from the Middle East and North Africa region is lacking.

**Objectives:** To determine the clinical features, management strategy, and outcomes of PTMC in a large tertiary care center in the United Arab Emirates (UAE).

**Patients and Methods:** This retrospective study included all patients diagnosed with PTMC (i.e., size ≤10 mm) at Tawam Hospital, Al Ain, UAE, between 2008 and 2019. Tumor histopathology, management strategy, and outcomes were the primary analyzed variables.

**Results:** A total of 213 patients with PTMC met the inclusion criteria, of which 83.6% were women and 58.7% were Emiratis. The majority had the classical tumor subtype (76.1%) and tumor of size 5–10 mm (71.4%). Multifocal disease was present in 41.1% and lymph node metastasis (LNM) in 16.6% of the patients. According to the 2015 American Thyroid Association categorization, the majority (93.9%) had a low-risk disease, and all except one patient had Stage 1 disease. Total thyroidectomy was performed in 91.1% of the patients, and 47.9% received radioiodine (RAI) therapy. None of the patients were under active surveillance strategy. RAI treatment was used more often in patients with non-incidental tumors, larger tumor size, multifocal disease, positive LNM, tumors in the intermediate/high ATA category, and those who underwent total thyroidectomy or neck dissection (for all, \( P < 0.05 \)). After a median follow-up of 32.4 months, about 73% had an excellent response to dynamic risk stratification assessment, and only one patient had disease recurrence.

**Conclusions:** The majority of the patients had low-risk PTMC, yet most patients underwent total thyroidectomy, and almost 50% were treated with RAI ablation. Further studies are needed to determine if these trends are also present regionally and to explore reasons for not adopting a less aggressive approach in this indolent tumor.

**Keywords:** Active surveillance, microcarcinoma, papillary, radioiodine, thyroid cancer, thyroidectomy
INTRODUCTION

Papillary thyroid microcarcinoma (PTMC), defined as a tumor of size ≤1 cm, represents about one-third of all thyroid cancer cases.\(^1\) Its incidence has significantly increased over the past three decades.\(^2\) Comprehensive use of head and neck imaging and fine-needle aspiration of small thyroid nodules are key factors contributing to this increase.\(^3\) The accurate pathological diagnosis of PTMC is paramount, as other benign conditions such as hyperplastic nodules, follicular adenomas, and Hashimoto’s thyroiditis may present some cytological features that mimic those in PTMC. Special attention to distinctive nuclear features including nuclear size, shape, chromatic pattern, and membrane irregularity as well as discussion of challenging cases in quality assurance meetings can assist in the accurate diagnosis of PTMC.

The prevalence of PTMC in autopsy studies is about 7–36%.\(^4\) However, only a small proportion is significant enough to reach clinical attention. Besides, most patients are free of disease after the initial surgery, whether lobectomy or total thyroidectomy, even when radioiodine (RAI) therapy is not administered, suggesting an indolent nature of PTMC.\(^5\)

In one study, about 70% of PTMC patients underwent active surveillance instead of immediate surgery and had no disease progression.\(^7\) These findings were replicated in other parts of the world and led to a remarkable shift in PTMC management, with several professional organizations now considering active surveillance as a valid option for many patients with PTMC.\(^8\)\(^–\)\(^11\)

Most studies on PTMC characteristics and management outcomes were conducted in countries outside the Middle East and North Africa region.\(^1\)\(^,\)\(^2\)\(^,\)\(^3\)\(^–\)\(^14\) Data from our group showed that from 2008 to 2018, there was a significant decline in RAI therapy, but not in surgery, in a wider cohort of thyroid cancer in the United Arab Emirates (UAE).\(^15\) Scoping of the current practice in PTMC management is crucial in light of an expected rise in the number of such patients in the future, especially in the absence of regional guidelines on the management of thyroid cancer. Therefore, the current study was conducted with the objective of determining PTMC patients’ characteristics, management patterns, and outcomes in a large referral center in the UAE over the past decade. We also aimed to identify clinicopathological features associated with lymph node metastasis and the use of RAI.

PATIENTS AND METHODS

Study design, population, and setting

This retrospective study included all patients diagnosed with PTMC (i.e., ≤10 mm) at Tawam Hospital, Al Ain, UAE, between September 2008 and December 2019. Details of the database has been reported previously.\(^15\) The study was approved by the local ethics committee.

Cases with incomplete histopathology data, non-papillary thyroid carcinoma, and non-invasive follicular-variant papillary thyroid carcinoma were excluded. The demographic and clinical data included age, gender, nationality, year of diagnosis, size of the tumor, location, multifocality, histopathological subtype, vascular invasion, nodal involvement, the extent of surgery, use of radioiodine ablation (RAI), and/or need for repeat surgery. The 8th edition of the American Joint Committee on Cancer TNM for staging. The 2015 American Thyroid Association (ATA) categorization was used for risk stratification.

Tawam Hospital is the largest oncology referral center in the country, and our thyroid cancer cohort represents both treatment-naive patients and those who received initial therapy (surgery with or without RAI) in outside facilities before visiting our center.

There is no local protocol for thyroid cancer management in our center. However, there are monthly thyroid cancer multidisciplinary team (MDT) meetings, where most cases are discussed for planning RAI therapy, follow-up investigations, and decision for additional treatments (radiotherapy or targeted therapy). The MDT comprises endocrinologists, ENT specialists, general surgeons who frequently perform thyroid surgeries, pathologist, nuclear medicine physicians, and radiologists. In addition, medical and radiation oncologists attend when required. The selection of cases for presentation at the MDT is at the discretion of the treating physicians. Furthermore, the decisions from the MDT help better guide the management of the discussed cases but are not considered obligatory, and the final decision remains at the discretion of the treating physicians.

Statistical analysis

Data were extracted into Microsoft Excel and analyzed using Stata version 16.0 (StataCorp, College Station, Texas, USA). Missing data were not treated, and only complete case analysis was performed. Quantitative variables were tabulated as mean ± standard deviation (SD) or median, minimum, and maximum, as appropriate. Qualitative variables were tabulated as frequencies and percentages (%). Chi-square or Fisher’s exact tests were performed to compare RAI and lymph node metastasis (LNM) with qualitative variables, as appropriate. In contrast, unpaired t-tests were performed to compare RAI and LNM with quantitative variables, as appropriate. P < 0.05 was considered statistically significant.
RESULTS

Demographics and tumor characteristics
A total of 213 patients of PTMC were included in the study [Table 1]. The mean age at diagnosis was 41.7 ± 12.0 years. The majority were female (83.6%) and UAE nationals (58.7%). The mean tumor size was 0.64 ± 0.3 cm, with the two most common histological subtypes being the classical (77.5%, 162/209) and follicular (18.2%, 38/209) variants. PTMC was an incidental finding in 65 cases (30.8%). Multifocal disease was present in 67 patients (41.1%), while only 3 (2%) and 5 (3.2%) patients had vascular invasion and extrathyroidal extension, respectively. Overall, most patients underwent total thyroidectomy (TT) (n = 194, 91.1%). Thyroiditis was found on histopathological examination in 69 patients (33.3%). Overall, the vast majority of patients (n = 199) had low-risk classification according to the ATA guideline criteria [Table 2]. Only one patient had Stage II disease: a 36-year-old female with a 1-cm multifocal sclerosing variant of papillary thyroid cancer, positive family history of thyroid malignancy, 10 of 39 positive lymph nodes, and evidence of lung metastasis. This patient underwent total thyroidectomy and neck dissection followed by RAI therapy.

Radioiodine treatment
RAI administration did not differ significantly among PTMC by tumor subtypes: 44.4% in classic, 52.6% in follicular, and 77.8% in the other subtypes. However, the proportion of patients who received RAI was significantly lower in those with incidental tumors (30.8%) than those with non-incidental malignancy (55.9%) (P = 0.001). The average tumor size was larger in patients receiving RAI compared with those not receiving RAI (0.71 ± 0.3 vs. 0.58 ± 0.3; P = 0.006). The rate of RAI treatment was 45.0% (89/198) in low-risk patients but increased in intermediate (91.0%, 10/11) or high-risk (100%, 2/2) category patients. Likewise, significantly high proportion of patients with multifocal tumors (67.2%), positive LNM (75.9%), and neck dissection (72.7%) received RAI compared with unifocal (34.4%), node-negative (40.0%), and no neck dissection patients (41.0%) [Table 3]. One patient initially underwent hemithyroidectomy and then completion surgery for a small nodule on the other lobe, which revealed a small focus of PTMC (0.3 cm) and was treated with RAI therapy.

Lymph node metastasis
Thirty-five of 211 patients with available data (16.6%) had a nodal disease. Compared with those without LNM, patients with LNM were younger (35.3 ± 10.6 years vs. 42.9 ± 11.9 years, respectively, P < 0.001) and had a larger tumor size (0.75 ± 0.2 vs. 0.62 ± 0.3, respectively; P = 0.025). The proportion of LNM was significantly (P < 0.001 each) higher in patients with intermediate/higher ATA risk (69.2%) and neck dissection (48.5%) than those with low ATA risk (13.2%) and without neck dissection (9.38%), respectively [Table 3].

Follow up and recurrence risk
After 32.4 months, most patients had an excellent response on the dynamic risk stratification at last visit. About a quarter of the patients had an indeterminate response (n = 45). Only one patient (0.5%) developed recurrence in the other lobe 10 years after lobectomy but had an excellent response on dynamic risk assessment at the last visit 7 months later.

DISCUSSION

The present study is the second-largest account of the characteristics of patients with PTMC in the Gulf region. The majority (77.5%) of our cohort had classical tumor subtype, which is slightly lower than studies from KSA (81.3%) and Philippines (90.3%).12,16 The median tumor size in this study was 0.6 cm, which is higher than reported in France but similar to other centers from the US (0.7 cm) and Italy (0.7 cm).1,2,17 Furthermore, the multifocal disease was present in about 41% of our patients, which is slightly higher than the reported rates in other studies (20.6 to 38%).2,13,14 Like other studies, most of our patients had a low-risk ATA classification.1,13

In the present study, LNM was reported in 16.6% of the patients, which lies within the 5–38% prevalence documented.
Malik, et al.: Papillary thyroid microcarcinoma in UAE

Table 2: Characteristics of study thyroid cancer, management details, and outcomes

| Variables (n) | n (%) |
|--------------|-------|
| subtype | n (%) |
| Classical | 162 (77.5) |
| Follicular | 38 (18.2) |
| Others | 9 (4.3) |
| incidental | 190 (93.1) |
| yes | 65 (30.8) |
| no | 146 (69.2) |
| Type of surgery | n (%) |
| Total | 194 (91.1) |
| Hemithyroidectomy | 19 (8.9) |
| stage | n (%) |
| stage 1 | 212 (99.5) |
| stage 2 | 1 (0.5) |
| rai therapy | n (%) |
| used | 102 (48.1) |
| dosage | 79.0 ± 37.2 mCi |
| tumor size | n (%) |
| <0.5 | 52 (26.6) |
| >0.5 | 130 (71.4) |
| mean±SD | 0.6 ± 0.3 |
| thyroiditis | n (%) |
| yes | 69 (33.3) |
| no | 138 (66.7) |
| ata risk stratification | n (%) |
| low | 199 (92.9) |
| indeterminate | 11 (5.2) |
| high | 2 (0.9) |
| Dynamic risk stratification | n (%) |
| indeterminate response | 45 (27.1) |
| Excellent response | 121 (72.9) |
| duration of follow-up | n (%) |
| months | 32.3 (0.4-1378.0) |
| laterализation | n (%) |
| bilateral | 44 (26.5) |
| isthmus | 6 (3.6) |
| left | 49 (29.5) |
| right | 67 (40.4) |
| Focality | n (%) |
| multifocal | 67 (41.1) |
| Unifocal | 96 (58.9) |
| Presence of local and distant spread | n (%) |
| vascular invasion | 3 (2.0) |
| extrathyroidal extension | 5 (3.2) |
| nodal involvement | 35 (16.6) |
| distant metastasis | 1 (0.5) |
| neck dissection | 33 (17.0) |
| Repeat surgery | n (%) |
| yes | 14 (6.9) |
| no | 190 (93.1) |

Only those with available data in each variable were included, other subtypes as follows: Oncocytic variant, n = 3; sclerosing, 2; tall cell, 1; poorly differentiated, 1; combination of oncocyic and hobnail, 1; and oncocyic and follicular, 1. RAI – Radiiodine; SD – Standard deviation; ATA – American Thyroid Association

in the literature. This wide range of nodal involvement could be attributed to the heterogeneity of the studied cohorts and the indication and extent of surgery. We found that younger age, tumor size (＞0.5 cm), ATA intermediate or high-risk category, and the extent of surgery were independent predictors of LNM. Similarly, in a large meta-analysis of 8345 patients with PTMC, central LNM was more common in men, young patients, and those with larger tumor size or multifocal disease. Recently, Luo et al. showed that not only male gender, age ＜40 years, and multifocality, but also tumors in the lower part of the thyroid lobe and the added size of all tumor foci are predictors of central LNM. Moreover, Kaliszewski et al. found higher rate of multifocal and bilateral disease in patients with LNM and suggested adopting a more aggressive approach in such patients. Nonetheless, the long-term outcomes remain favorable in those with bilateral multifocal than unifocal disease, with a similar recurrence risk after a median follow-up of 60 months.

Distant metastasis is rare in PTMC with a prevalence of 0.1–2.7%. Only one patient in our cohort had distant metastasis at diagnosis. This patient had multiple risk factors: larger tumor size, extensive cervical lymphadenopathy, and a positive family history of thyroid malignancy.

Management of papillary thyroid carcinoma in general, and PTMC with low-risk features specifically, has evolved to a less aggressive approach over the past two decades. Most of our patients underwent total thyroidectomy, which is similar to another study from KSA. This rate is much higher than those reported in studies from Canada, China, and France, where total thyroidectomy was performed in 48%, 79%, and 80% of the patients, respectively. This discrepancy may relate to multiple factors such as tumor characteristics, patient and/or physician preferences, the initial indication for surgery, and the ease of follow up. In a Canadian survey where 113 physicians (55.8% endocrinologists, 44.2% ENT surgeons) were asked to select their therapy of choice in a hypothetical case of a young female with 0.8-cm biopsy-proven papillary thyroid carcinoma, hemithyroidectomy was selected by 47% of the participants compared with 43% for TT, with a minority opting for non-operative or more aggressive surgical intervention. More participants selected TT as the treatment option when additional risks were added to the case, such as the history of radiation exposure and family history of cancer as well as with a different gender. This is not surprising, as physicians try to optimize their patients’ surgical treatment, especially those with risk factors for aggressive disease, knowing that TT has better outcomes in reducing long-term recurrence risk than lobectomy. Furthermore, the recommendation to limit surgery’s extent has received more attention in the latest 2015 ATA guidelines than the prior version from 2009.

Several studies have shown that RAI use is not associated with reduced recurrence (locoregional or distance) or mortality in patients with PTMC. Conversely, a recent large meta-analysis of 22 studies of 8724 patients suggested a lower risk of locoregional disease recurrence in those who...
received RAI (1.9 vs. 7.4%; \( P = 0.08 \)). In our study, almost half of the patients received RAI ablation. This rate is higher than those reported from the USA and France (15% and 21% respectively). As the number of patients classified with intermediate/high-risk by ATA criteria and those with nodal or distant metastasis is small in our study, RAI therapy is over-prescribed in our cohort. Nonetheless, there was a similar RAI usage rate in the studies from KSA, Philippines, and China. In addition, in a recent study from Chile, about 88% of PTMC patients who underwent total thyroidectomy received RAI ablation. The absence of high-quality data on RAI’s role in this population might considerably affect its use across different studies.

Intriguingly, none of our patients underwent active surveillance for PTMC, despite the recent guidelines suggesting it as an alternative option instead of immediate surgery. However, it is essential to note that the concept of active surveillance was first introduced in Japan in 1993, and it was not until about 20 years later that it gained popularity in the same center, and was only been introduced as a viable option in Japanese guidelines in 2010. Since

**Table 3: Patient and disease characteristics by use of radioiodine therapy and presence of lymph node metastasis**

| Variable                                      | RAI therapy | P     | LNM  | P     |
|-----------------------------------------------|-------------|-------|------|-------|
|                                               | Yes         | No    |      |       |
| Years                                         |             |       |      |       |
| Before 2009                                   | 8 (57.1)    | 6 (42.9) | 0.372 | 1 (7.69) | 12 (92.3) | 0.474 |
| 2009-2015                                     | 50 (52.1)   | 46 (47.9) | 14 (14.4) | 83 (85.6) |
| 2016-2019                                     | 44 (43.1)   | 58 (56.9) | 20 (19.8) | 81 (80.2) |
| Age                                           | 41.6±12.2   | 41.8±12.0 | 0.940 | 35.3±10.6 | 42.9±12.0 | <0.001 |
| Sex                                           |             |       |      |       |
| Female                                        | 84 (47.5)   | 93 (52.5) | 0.667 | 29 (16.4) | 148 (83.6) | 0.458 |
| Male                                          | 18 (51.4)   | 17 (48.6) | 6 (17.7) | 28 (82.4) |
| Ethnicity                                     |             |       |      |       |
| UAE national                                  | 53 (42.7)   | 71 (57.3) | 0.063 | 25 (20.3) | 98 (79.7) | 0.084 |
| Expatriates                                   | 49 (55.7)   | 39 (44.3) | 10 (11.4) | 78 (88.6) |
| Family history of thyroid cancer              |             |       |      |       |
| No                                            | 92 (46.9)   | 104 (53.1) | 0.262 | 31 (16.0) | 163 (84.0) | 0.323 |
| Yes                                           | 5 (71.4)    | 2 (28.6) | 2 (28.6) | 5 (71.4) |
| Subtype                                       |             |       |      |       |
| Classical                                     | 72 (44.4)   | 90 (55.6) | 0.116 | 25 (15.6) | 135 (84.4) | 0.080 |
| Follicular                                    | 20 (52.6)   | 18 (47.4) | 5 (13.2) | 33 (86.8) |
| Other                                         | 7 (77.8)    | 2 (22.2) | 4 (44.4) | 4 (55.6) |
| Incidental                                    | 81 (55.9)   | 64 (44.1) | 0.001 | 27 (18.6) | 118 (81.4) | 0.320 |
| Total thyroidectomy                           | 101 (52.3)  | 92 (47.7) | <0.001 | 35 (18.2) | 157 (81.8) | 0.048 |
| Hemithyroidectomy                             | 0           | 18 (94.7)* |       | 0      | 19 (100.0) |       |
| Tumor size (mm)                               |             |       |      |       |
| Mean±SD                                       | 0.7±0.3     | 0.6±0.3 | 0.006 | 0.7±0.2 | 0.6±0.3 | 0.025 |
| <0.5                                          | 19 (36.5)   | 33 (63.5) | 0.044 | 2 (3.8) | 50 (96.2) | 0.001 |
| >0.5                                          | 69 (53.1)   | 61 (46.9) | 30 (23.1) | 100 (76.9) |
| Evidence of thyroiditis                       |             |       |      |       |
| No                                            | 67 (48.6)   | 71 (51.5) | 0.689 | 19 (13.9) | 118 (86.1) | 0.164 |
| Yes                                           | 31 (45.6)   | 37 (54.4) | 15 (22.1) | 53 (77.9) |
| American thyroid association risk level        |             |       |      |       |
| Indeterminate/high                            | 12 (92.3)   | 1 (7.7) | 0.001 | 9 (69.2) | 4 (30.8) | <0.001 |
| Low                                           | 89 (45.0)   | 109 (55.1) | 26 (13.2) | 171 (86.8) |
| Lateralization, locality, and side            |             |       |      |       |
| Bilateral                                     | 27 (61.4)   | 17 (38.6) | 0.056 | 7 (15.9) | 37 (84.1) | 0.971 |
| Isthmus                                       | 1 (16.7)    | 5 (83.3) | <0.001 | 1 (16.7) | 5 (83.3) | 1.000 |
| Left                                          | 23 (47.0)   | 26 (53.1) | 7 (14.3) | 42 (85.7) |
| Right                                         | 26 (38.8)   | 41 (61.2) | 12 (17.9) | 55 (82.1) |
| Multifocal                                    | 45 (67.2)   | 22 (32.8) | 11 (16.7) | 55 (83.3) |
| Unifocal                                      | 33 (34.4)   | 63 (65.6) | 16 (16.7) | 80 (83.3) |
| LNM                                           |             |       |      |       |
| No                                            | 78 (44.6)   | 97 (55.4) | 0.048 | -      | -      | -     |
| Yes                                           | 22 (62.9)   | 13 (37.1) | -      | -      | -      | -     |
| Neck dissection                               |             |       |      |       |
| No                                            | 66 (41.0)   | 95 (59.0) | 0.001 | 15 (9.4) | 145 (90.6) | <0.001 |
| Yes                                           | 24 (72.7)   | 9 (27.3) | 16 (48.5) | 17 (51.5) |

*One patient had completion thyroidectomy and received RAI. RAI – Radioiodine; SD – Standard deviation; UAE – United Arab Emirates; LNM – Lymph node metastasis*
then, few centers worldwide (Korea and the USA) reported their experience with active surveillance.[9,10] In the USA, the vast majority of patients with PTMC were treated surgically, with a slight increase in the rate of non-operative management in 2015 compared to 2006 (0.6 vs. 0.9%; \( P = <0.001 \).)[9,10] Furthermore, the acceptance for the active surveillance approach was low in recent single-center studies from Argentina (25%) and Italy (50%).[36,37] Therefore, active surveillance is not yet widely adopted, and only well informed and carefully selected low-risk PTMC patients who can follow up regularly in thyroid cancer clinics might be offered this option.

The majority of our patients had an excellent response to therapy at their last follow-up assessment, with tumor recurrence occurring only in 0.5% of the cohort. This rate is much lower compared to other studies.[11-14] This could be related to the shorter follow-up period in the present study. In addition, it is unclear if the extent of surgery and the higher use of RAI hast impacted our results. As expected, none of our patients died because of PTMC, confirming the indolent nature of this tumor, in line with the published data.[1,2]

Our study has some limitations. First, it is a retrospective study and data on indications for performing thyroid ultrasound, patients’ selection for FNA, outcomes of FNA, and reasons behind type of surgery as well as radioiodine dose were not consistently available. Further, the findings are an experience from a single tertiary referral center and may not necessarily reflect the practice in other centers. In addition, we have no established thyroid cancer treatment and follow-up protocol, and the data may reflect the practice of physicians from different schools of training.

**CONCLUSIONS**

Most patients in this study had low-risk PTMC, with rare occurrence of distant metastasis or tumor recurrence on follow-up, yet most underwent total thyroidectomy, and about half received the RAI therapy. Additional studies are needed to determine if these trends are also present regionally and to explore factors behind the high use of total thyroidectomy and RAI ablation rather than active surveillance in patients with the indolent PTMC.

**Acknowledgment**

The authors would like to thank Mr. Anvar Kandanath, Health Information Management Division, Tawam Hospital, UAE, for his support in data retrieval and management. The authors are also thankful to Dr. Abdulghani Elmomami, Union 71 Medical Facilities Management LLC, UAE, for his advice on revising the histopathology part of the manuscript.

**Ethical considerations**

The Al Ain Medical District Human Research Ethics Committee approved the study (Ref no: THREC-562; dated: February 21, 2018). As this is a retrospective study, patient consent was not specifically sought from patients for this study; however, all patients at the hospital provide a general consent for anonymous use of their data for education, research, and quality assurance. The study adhered to the principles of the Declaration of Helsinki, 2013.

**Data availability statement**

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.
Peer review
This article was peer-reviewed by two independent and anonymous reviewers.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery 2008;144:980-7.
2. Zalzali M, Dehreuve A, Richarda C, Filieric H, Schwartz C. Micropapillary carcinoma: Description and rise in incidence in the French Marne-Ardennes thyroid cancer registry Ann Endocrinol 2019;80:229-33.
3. Navarra G, Zanghi GN, Freni F, Galletti B, Galletti F, Pagano G, et al. Treatment decision making in papillary thyroid microcarcinoma. J Endo Surg 2018;18:110-20.
4. Lang W, Borruch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 1988;90:72-6.
5. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma: Description and rise in incidence in the French Marne-Ardennes thyroid cancer registry Ann Endocrinol 2019;80:229-33.
6. Pollack R, Mazeh H. Active surveillance of thyroid microcarcinoma: Can this approach be safely implemented worldwide? J Surg Res 2021;258:145-52.
7. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381-7.
8. Kwon H, Oh HS, Kim M, Park S, Jeon MJ, Kim WG, et al. Active surveillance for patients with papillary thyroid microcarcinoma: A single center's experience in Korea. J Clin Endocrinol Metab 2017;102:1917-25.
9. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017;143:1015-20.
10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
11. Yi KH, Lee EK, Kang HC, Kim SW, Kim JI, Na DG, et al. 2016 revised Korean Thyroid Association Management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol 2016;9:59-126.
12. Rosti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: A descriptive and meta-analysis study. Eur J Endocrinol 2008;159:659-73.
13. Guerrero RJ, Małong CL, Caringal JA, Sio C, De Villa VG, Kho S. Clinical, surgical and histopathologic outcomes of Filipino patients with micropapillary thyroid carcinoma in a tertiary university hospital in the Philippines. J ASEAN Fed Endo Soc 2014;29:72.
14. Gao R, Jia X, Liang Y, Fan K, Wang X, Wang Y, et al. Papillary thyroid micro carcinoma: The incidence of high-risk features and its prognostic implications. Front Endocrinol (Lausanne) 2019;10:74.
15. Azhar M, Aziz F, Almuhairi S, Alfelasi M, Elhouani A, Syed R, et al. Decline in radioiodine use but not total thyroidectomy in thyroid cancer patients treated in the United Arab Emirates: A retrospective study. Ann Med Surg (Lond) 2021;4:64:102203.
16. Al-Qahtani KH, Al Asiri M, Tunio MA, Aljohani NB, Bayoumi Y, Fatani H, et al. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected]. J Otolaryngol Head Neck Surg 2015;44:51.
17. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna I, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: Results of a study in 445 patients. Thyroid 2009;19:707-16.
18. Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, Cao YM, et al. Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: A meta-analysis. World J Surg 2015;39:2459-70.
19. Luo Y, Zhao Y, Chen K, Shen J, Shi J, Lu S, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest 2019;42:227-36.
20. Kaliszewski K, Diakowska D, Wojtak B, Forkasiewicz Z, Pupka D, Nowak I, et al. Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? World J Surg Oncol 2019;17:91.
21. Yan T, Qiu W, Song J, Ying T, Fan Y, Yang Z. Bialateral multifocality, a marker for aggressive disease, is not an independent prognostic factor for papillary thyroid microcarcinoma: A propensity score matching analysis. Clin Endocrinol (Oxf) 2021;95:299-16.
22. Merdad M, Eskander A, De Almeida J, Freeman J, Roststein I, Ezzat S, et al. Current management of papillary thyroid microcarcinoma in Canada. J Otolaryngol Head Neck Surg 2014;43:32.
23. Zheng W, Li J, Lv P, Chen Z, Fan P. Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: A systemic review and meta-analysis. Eur J Surg Oncol 2018;44:1679-84.
24. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer Coopr DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
25. Hu G, Zhu W, Yang W, Wang H, Shen L, Zhang H. The effectiveness of radioactive iodine remnant ablation for papillary thyroid microcarcinoma: A systematic review and meta-analysis. World J Surg 2016;40:100-9.
26. Kim HJ, Kim SW. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2013;79:945-54.
27. Yang T, Zheng SY, Jiao J, Zou Q, Zhang Y. Radioiodine remnant ablation in papillary thyroid microcarcinoma: A meta-analysis. Nucl Med Commun 2019;40:711-9.
28. Domínguez JM, Niño F, Martínez MT, Massardo JM, Muñoz S, Contreras T, et al. Papillary thyroid microcarcinoma: Characteristics at presentation, and evaluation of clinical and histological features associated with a worse prognosis in a Latin American cohort. Arch Endocrinol Metab 2018;62:6-13.
29. Nowak Ł, Prinz RA. Trends in non-operative management of papillary thyroid nodules and differentiated thyroid tumors. Tokyo: Kanehara & Co., Ltd; 2010. p. 1‑199.
30. Holoubek SA, Yan H, Kuehla KM, Winchester DJ, Moo‑Young TA, Prinz RA. Trends in non‑operative management of papillary thyroid microcarcinoma. J Surg Oncol 2020;121:952‑7.
31. Smulever A, Pitoia F. Active surveillance in papillary thyroid carcinoma: Not easily accepted but possible in Latin America. Arch Endocrinol Metab 2019;63:462‑9.
32. Molinaro E, Campopiano MG, Pieruzzi L, Matrone A, Agate I, Bottici V, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: Experience at a single Italian center. J Clin Endocrinol Metab 2020;105:113.